Ropivacaine hydrochloride
ApprovedSmall molecule
Shanghai Hengrui Pharmaceutical Co., Ltd.Ropivacaine hydrochloride is one of 91 small molecule programs targeting Mastectomy. It is currently in Approved.
4
Indications
10
Total Trials
2
Active Trials
90
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
378 competitors in Bladder Cancer
#DrugCompanyPhaseTrials
1Gemzar
Johnson & JohnsonPhase 3
Platinol
MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.
Phase 3
Taxol
TevaPhase 3
Trexall
Alnylam PharmaceuticalsPhase 3
Adriamycin
PfizerPhase 3
Javlor
Bristol-Myers SquibbPhase 3
Taxotere
AAvyxa
Phase 3
Paraplatin
AAvyxa
Phase 3
Entereg
Merck & Co.Phase 3
Mitomycin C
GGynecologic Oncology Group
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Postsurgical Pain Management2 trials
Mastectomy1 trial
PEMF and PEC Blocks in Mastectomy Reconstruction Patients
Completed·—·Phase 4·NCT03360214·60 enrolled
Cesarean Section1 trial
Suprascapular Nerve Block1 trial
4 more indications
Postoperative Analgesia1 trial
A Clinical Trial Evaluating the Efficacy, Safety, and Pharmacokinetic Profile of TRD303 for Postoperative Analgesia After Abdominal Surgery in China.
Enrolling by invitation·TThe Third Xiangya Hospital of Central South University·Phase 3·NCT07353307·333 enrolled
Bladder Cancer1 trial
Patient-Controlled Analgesia1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Ropivacaine hydrochloride. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details